Monte Rosa Therapeutics (GLUE) Operating Margin (2024 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Operating Margin of 1163.58% in Q1 2026, down 748.21% quarter-over-quarter from 137.18% in Q4 2025, and down 121543.0% on a YoY basis from N/an in Q1 2025.
Monte Rosa Therapeutics (GLUE) Operating Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Operating Margin history runs 3 years deep, the most recent figure standing at 1163.58% for Q1 2026.
- In Q1 2026, Operating Margin fell 121543.0% year-over-year to 1163.58%; the TTM figure through Mar 2026 stood at 2380.88% (down 237955.0% YoY), while the FY2025 annual figure was 6.72%, up 10054.0% from the prior year.
- Operating Margin was 1163.58% for Q1 2026 at Monte Rosa Therapeutics, down from 137.18% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 51.85% in Q1 2025 to a low of 3284.49% in Q1 2024.
- Historically, Operating Margin has averaged 620.45% across 3 years, with a median of 137.18% in 2025.
- The sharpest annual moves came in 2025 and 2026: Operating Margin surged 333634 bps in 2025, then slumped 121543 bps in 2026.
- A 3-year view of Operating Margin shows it stood at 21.44% in 2024, then plunged by 740 bps to 137.18% in 2025, then plunged by 748 bps to 1163.58% in 2026.
- The last three Operating Margin figures came in at 1163.58% (Q1 2026), 137.18% (Q4 2025), and 21.98% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -1,163.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,163.58% |
| Dec 31, 2025 | -137.18% |
| Sep 30, 2025 | -21.98% |
| Jun 30, 2025 | -67.06% |
| Mar 31, 2025 | 51.85% |
| Dec 31, 2024 | 21.44% |
| Sep 30, 2024 | -287.84% |
| Jun 30, 2024 | -695.25% |
| Mar 31, 2024 | -3,284.49% |